Drugs / MF59C.1-adjuvanted subunit influenza vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01342796 | May 2011 → Feb 2012 | influenza | Novartis Vaccines | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MF59C.1-adjuvanted subunit influenza vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01342796 ↗ |
| Known as | ATIV | “This phase II, randomized clinical trial was conducted to evaluate the antibody and cell-mediated responses to a trivalent influenza vaccine administered without adjuvant (TIV)...” PMID 25037034 ↗ Jan 2015 |
| Modality | Vaccine | “a MF59C.1-adjuvanted subunit influenza vaccine” NCT01342796 ↗ |
| Route | Intramuscular | “2 x 0.25 ml doses administered intramuscularly in the deltoid muscle of (preferably) the non dominant arm” NCT01342796 ↗ |